The 53 references in paper O. KUZMIN V., О. КУЗЬМИН Б. (2011) “МЕХАНИЗМЫ РАЗВИТИЯ И ПРОГРЕССИРОВАНИЯ НЕФРОПАТИИ У БОЛЬНЫХ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ С ХРОНИЧЕСКИМ КАРДИОРЕНАЛЬНЫМ СИНДРОМОМ // MECHANISMS OF NEPHROPATHY DEVELOPMENT AND PROGRESSION IN HEART FAILURE PATIENTS WITH CHRONIC CARDIORENAL SYNDROME” / spz:neicon:nefr:y:2011:i:2:p:20-29

1
Ronco C, McCullough P, Anker SD et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31 (6): 703-711
(check this in PDF content)
2
Smith GL, Lichtman JH, Bracken MG et al. Renal impairment and outcomes in heart failure. Systemic review and meta-analysis. J Am Coll Cardiol 2006; 47 (10): 1987-1996
(check this in PDF content)
3
Masson S, Latini R, Milani V et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from GISSI-Heart Failure trial. Circ Heart Fail 2010; 3 (1): 65-72
(check this in PDF content)
4
Jackson CE, Solomon SD, Gerstein HC et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374 (9689): 543-550
(check this in PDF content)
5
Yoshida H, Yashiro M, Ping Liang et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int 1998; 53 (4): 880-891
(check this in PDF content)
6
Kjaer A, Hesse B. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspective. Clin Physiol 2001; 21 (6): 661-672
(check this in PDF content)
7
Remes J, Tikkanen I, Fyhrqust F, Pyorala K. Neuroendocrine activity in untreated heart failure. Brit Heart J 1991; 65 (2): 249-255
(check this in PDF content)
8
Ситникова МЮ, Беляева ОД, Сычева ЮА и др. Гемодинамические и локальные натрийуретические системы почек при начальных стадиях сердечной недостаточности. Влияние длительной терапии периндоприлом. Кардиология 2000; 40 (9): 64-68
(check this in PDF content)
9
Ljungman S., Laragh J.H., Cody R.J. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 1990; 39 [Suppl. 4]: 10-21
(check this in PDF content)
10
Margi P, Rao A, Cangianiello S et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation 1998; 98 (25): 28-49-2854
(check this in PDF content)
11
Nishikimi T, Ochino K, Frohlich ED. Effects of alpha 1adrenergic blockade on intrarenal hemodynamics in heart failure rats. Am J Physiol 1992; 262 (2, Pt 2): R198-R203
(check this in PDF content)
12
Numabe A, Komatsu K, Frohlich ED. Intrarenal hemodynamics in low- and high-output cardiac failure rats. Am J Med Sci 1994; 308 (6): 331-337
(check this in PDF content)
13
Yoshida H, Matsushima H. Machiguchi T et al. Glomerular hyperfiltration and sclerosis in chronic heart failure. J Am Soc Nephrol 1995; 6 (3): 689 (Abstract)
(check this in PDF content)
14
Кузьмин ОБ, Бучнева НВ, Пугаева МО. Почечные гемодинамические механизмы формирования гипертонической нефропатии. Нефрология 2009; 13 (4): 28-36
(check this in PDF content)
15
Акаемова ОН, Коц ЯИ, Синицын ВЕ. Состояние периферической и внутрисердечной венозной системы сердца при хронической сердечной недостаточности. Тер архив 2009; 81 (12): 27-30
(check this in PDF content)
16
Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated renal failure. J Am Coll Cardiol 2009; 53 (7): 589-596
(check this in PDF content)
17
Damman K, Van Deursen VM, Navis G et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53 (7): 582558
(check this in PDF content)
18
Abildgaard U. Hemodynamics and functional changes during renal venous stasis in dog kidney. Dan Med Bull 1989; 36 (3): 212-222
(check this in PDF content)
19
Doty JM, Saggi BH, Sugerman HJ et al. Effect of increased renal venous pressure on renal function. J Trauma 1999; 47 (6): 1000-1003
(check this in PDF content)
20
Bresis M, Rosen S, Silva P, Epstein FH. Renal ischemia: A new perspective. Kidney Int 1984; 26 (4): 375-383
(check this in PDF content)
21
Higgins DF, Kimura K, Iwano M, Haase VH. Hypoxiainducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008; 7 (9): 1128-1132
(check this in PDF content)
22
Bemhardt WM, Campean V, Kany S et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J AM Soc Nephrol 2006; 17 (7): 1970-1980
(check this in PDF content)
23
Song YR, You SJ, Lee YM et al. Activation of hypoxiainducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant 2010; 25 (1): 77-85
(check this in PDF content)
24
Orphanides C, Fine LG, Norman JT. Hypoxia stimulates proximal tubular cell matrix production via a TGF-β1independent mechanism. Kidney Int 1997; 52 (3): 637-647
(check this in PDF content)
25
Norman JT, Fine LG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol 2006; 33 (10): 989-996
(check this in PDF content)
26
Neumann AK, Yang J, Biju MP et al. Hypoxia inducible factor 1б regulates T-cell receptor signal transduction. Proc Natl Acad Sci 2005; 102 (47): 17071-17076
(check this in PDF content)
27
Poyton RO, Ball KA, Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab 2009; 20 (7): 332-340
(check this in PDF content)
28
Subtirelu M, Gershin I, Teichman J, Tufro A. A novel model of chronic hypoxia-induced glomerulomegaly (Abstract). J Am Soc Nephrol 2005; 16: 668A
(check this in PDF content)
29
Brukamp K, Jin B, Moeller M, Haase VH. Hypoxia and podocyte-specific Vhlh deletion confer risk of glomerular disease. Am J Physiol Renal 2007; 293 (4): F1397-F1407
(check this in PDF content)
30
Neusser MA, Lindenmeyer MT, Moll AG et al. Human nephrosclerosis triggers a hypoxia-related glomerulopathy. Am J Pathol 2010; 176 (2): 594-607
(check this in PDF content)
31
Rodriquez-Diez R, Carvajal-Gonzales G, Sancher-Lopes E et al. Pharmacological modulation of epithelial-mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008; 25 (10): 2447-2461
(check this in PDF content)
32
Nangaki M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17 (1): 17-25
(check this in PDF content)
33
Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74 (7): 867-872
(check this in PDF content)
34
Higgins DF, Kimura K, Bernhardt WM et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelialto-mesenchymal transition. J Clin Invest 2007; 117 (12): 38103820
(check this in PDF content)
35
Sun S, Ning X, Zhang Y et al. Hypoxia-inducible factor 1 alpha induces Twist expression in tubular epithelial cells subjected to hypoxia leading to epithelial-to-mesenchymal transition. Kidney Int 2009; 75 (12): 1278-1287
(check this in PDF content)
36
Guo LP, Huang HC, Li JZ. Hypoxia induces the expression and secretion of connective tissue growth factor and fibronectin by cultured renal cortical myofibroblasts. Beijing Da Hue Bao 2007; 39 (1): 67-71
(check this in PDF content)
37
Namba S, Okuda Y, Morimoto A et al. Indoxyl sulfate is a useful predictor for progression of chronic kidney disease. Rinsho Byori 2010; 58 (5): 448-453
(check this in PDF content)
38
Miyazaki T, Ise M, Seo H et al. Indoxyl sulfate increases the gene expression of TGF-в1, TIMP-1 and proб(1) collagen in uremic rat kidney. Kidney Int 1997; 52 [Suppl]: S15-S22
(check this in PDF content)
39
Motojima M, Hosokawa A, Yamamoto H et al. Uremic toxins of organic anions upregulate PAI-1 expression by induction of NF-kB and free radicals in proximal tubular cells. Kidney Int 2003; 63 (6): 1671-1680
(check this in PDF content)
40
Gelasco AK, Raymond JR. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal 2006; 290 (6): F1551-1558
(check this in PDF content)
41
Namba S, Okuda Y, Morimoto A et al. A serum indoxyl sulfate is a useful predictor of chronic kidney disease. Rinsho Byori 2010; 58 (5): 448-453
(check this in PDF content)
42
Shibahara H, Shibahara N. Cardiorenal protective effects of the oral uremic toxin adsorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010; 23 (5): 535-540
(check this in PDF content)
43
Ahmed A, Love TE, Sui X, Rich MW. Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis. J Card Fail 2006; 12 (7): 499-506
(check this in PDF content)
44
Berger AK, Duvals S, Manske C et al. Angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153 (6): 1064-1073
(check this in PDF content)
45
Whaley-Connell A, Habibi J, Johnson M et al. Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ran2 rat. J Am Nephrol 2009; 30 (4): 356-360
(check this in PDF content)
46
Wong WY, Laping NG, Helson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGFв expression. Brit J Pharmacol 2001; 134 (5): 977-984
(check this in PDF content)
47
Cohen-Solal A, Kotecha D, van Veldhuisen DJ et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from RENIORS trial. Eur J Heart Fail 2009; 11 (9): 872-880
(check this in PDF content)
48
Groenveld HF, Januzzi JC, Damman K et al. Anemia and mortality in heart failure patients. A systematic review and meta-analysis. J Am Coll Cardiol 2008; 52 (10): 818-827
(check this in PDF content)
49
Palazzuoli A, Qvatrini I, Calabro A et al. Anemia correction by erythropoietin reduces BNP levels, hospitalization rate and NYHA class in patients with cardio-renal anemia syndrome. Clin Exp Med 2010;
(check this in PDF content)
50
Ahmed A, Husain A, Love TE et al. Heart failure, chronic diuretic use and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006; 27 (12): 1431-1439
(check this in PDF content)
51
Ahmed A, Young JB, Love TE et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008; 125 (2): 246-253
(check this in PDF content)
52
Tamirisa KP, Aaronson KD, Koelling TM. Spironolactoneinduced renal insufficiency and hyperkaliemia in patients with heart failure. Am Heart J 2004; 148 (6): 971-978
(check this in PDF content)
53
Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная недостаточность 2009; 10 (2): 64-106 Ïîñòóïèëà â ðåäàêöèþ 15.09.2010 ã. Ïðèíÿòà â ïå÷àòü 09.02.2011 ã.
(check this in PDF content)